The Present and Future of Insulin Therapy Part 13

October 27th, 2015

Oct 27, 2015
3,810 views

In this week’s Homerun Slides, the results of a multinational, placebo-controlled, randomized, double-blind, parallel-group, 24-week study involving patients who were receiving insulin (not routine pre-meal short- or rapid-acting insulin, except as pre-mixed insulin) administered alone or in combination with metformin (³1500 mg per day) and who had inadequate glycemic control (A1C ³7.5% and ≤11%).

To download the complete set in PowerPoint format, just use this link:

ThePresentandFutureofInsulinTherapyinEraofPathophysiologicTxofT2DMPart13

Catch up on past Homerun Slides for The Present and Future of Insulin Therapy series.

To download part 12, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 12

To download part 11, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 11

To download part 10, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 10

To download part 9, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 9

To download part 8, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 8

To download part 7, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 7

To download part 6, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 6

To download part 5, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 5

To download part 4 and for links to parts 1 through 3, click here: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 4